In this episode, Richard Church and Victoria Hamscho discuss recent developments in the 340B Drug Pricing Program, including recent COVID-19 guidance by the Health Resources and Services Administration and hospital requests...more
4/9/2020
/ Coronavirus/COVID-19 ,
Covered Entities ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
DSH ,
DSH Adjustments ,
Eligibility Determination ,
Emergency Response ,
Group Purchasing Organizations (GPO) ,
Health Care Providers ,
Hospitals ,
HRSA ,
Medicaid ,
Medical Records ,
Medicare ,
Pharmaceutical Industry ,
Prescription Drugs ,
Section 340B ,
Social Security ,
Telehealth
On Wednesday, March 25, a historic, bipartisan deal was reached in the Senate to offer $2 trillion in health care and economic relief to Americans and businesses amid the ongoing novel coronavirus (COVID-19) pandemic. The...more
On March 14, the House of Representatives passed the Families First Coronavirus Response Act (H.R. 6201), as amended, in a 363-40 vote; the House subsequently passed an amended version of the measure on March 16 containing...more
As the novel coronavirus (COVID-19) continues to spread globally and the number of cases in the U.S. grows, attention on Capitol Hill has shifted to potential legislative responses aimed at combatting the outbreak and...more
On February 7, 2020, the Centers for Medicare & Medicaid Services (“CMS”) issued a notice relating to the agency’s intention to survey hospitals about their acquisition costs for specified covered outpatient drugs (“SCODs”)...more
In this episode, Macy Flinchum and Victoria Hamscho discuss recent developments in the 340B Drug Pricing Program, including recent guidance by the Centers for Medicare and Medicaid Services on best practices for states to...more
1/30/2020
/ Best Practices ,
Centers for Medicare & Medicaid Services (CMS) ,
Covered Entities ,
Discounts ,
Drug Pricing ,
Fee-for-Service ,
Health Care Providers ,
MCOs ,
Medicaid ,
Medicaid Drug Rebate Program ,
New Guidance ,
Pharmaceutical Industry ,
Prescription Drugs ,
Section 340B
In this episode, Ryan Severson and Victoria Hamscho discuss recent developments in pharmaceutical pricing and the 340B Drug Pricing Program heading into 2020, including reimbursement cuts for 340B drugs under the Outpatient...more
12/20/2019
/ Centers for Medicare & Medicaid Services (CMS) ,
Drug Pricing ,
Executive Orders ,
Final Rules ,
Health Care Providers ,
Hospitals ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Outpatient Prospective Payment System (OPPS) ,
Pharmaceutical Industry ,
Pharmacies ,
Pharmacy Benefit Manager (PBM) ,
Physicians ,
Prescription Drugs ,
Proposed Legislation ,
Reimbursements ,
Section 340B
Forty-six states currently have marijuana legalization laws. Twenty-nine states and the District of Columbia have legalized medical marijuana, while seventeen states have allowed access to certain strains for some medical...more
In the face of controversy and following thousands of comments from market participants and lawmakers, the Department of Labor (“DOL”) has finalized sweeping changes to the definition of “fiduciary” under the Employee...more